Page 10 - Monitoring Prostate Cancer to Guide Treatment Decision-Making

Natural History of Prostate Cancer

CHAARTED Docetaxel + ADT
GETUG-AFU 15 Docetaxel + ADT
STAMPEDE Docetaxel + ADT
Abiraterone + ADT
de novo LATITUDE Abiraterone + ADT
mets

Metastatic
HSPC
(mHSPC)
TAX327 Docetaxel + ADT
COU-AA 301 Abiraterone + ADT
Localized Metastatic COU-AA-302 Abiraterone + ADT
prostate CRPC AFFIRM Enzalutamide + ADT
cancer PREVAIL Enzalutamide + ADT
(mCRPC) TROPIC Cabazitaxel + ADT

Non- ALSYMPCA Radium-223 + ADT
Non-
metastatic metastatic
CRPC
HSPC
(nmCRPC)
ADT
PROSPER Enzalutamide + ADT
SPARTAN Apalutamide + ADT

Adapted from Aggarwal RR, et al. Oncology (Williston Park) 2017; 31(6):467-74. 10